Akamis Bio to Present Phase 1 NG-348 Data at SITC 2026
Akamis Bio says it will present data from a Phase 1 study of NG-348 in patients with advanced epithelial tumors at SITC 2026.
Akamis Bio says it will present data from a Phase 1 study of NG-348 in patients with advanced epithelial tumors at SITC 2026.